Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.
A port delivery system with ranibizumab with dosing every 24 weeks has been shown in a Phase III trial to be equivalent to monthly intravitreal ranibizumab injection to treat neovascular age-related macular degeneration, according to Dr Carl Regillo, who reported on behalf of the Archway Trial investigators.
Heads-up surgery is moving into the next generation of vitreoretinal surgery, with novel technologies being developed for surgeons.
The first reported clinical results of a Phase I study following implantation of the 3-D neural interface retinal prosthesis showed it is safe in patients with end-stage retinitis pigmentosa.
Investigators find that nanoparticles deliver gene therapy successfully in mice, rats
Automated assistance controls tremor, reduces fatigue, and helps avoid inadvertent injury
Ophthalmologists remain in touch with colleagues while maintaining social distancing
This ability would unlock possibilities for repairing tissue damaged by disease
Watchful waiting may prove to be beneficial in complicated cases
Intravitreal gene therapy continues to be well tolerated; shows robust efficacy
Though OCTA has become indispensable for managing macular degeneration and diabetic retinopathy, Robert L. Stamper, MD, explains why the technology must become more sophisticated and evolved before it reaches its full potential for glaucoma specialists.
Find out how the LIGHTSITE I results may pave the way for a new treatment approach.
The FDA has issued an emergency use authorization to allow treatment with COVID-19 convalescent plasma for patients who are hospitalized with the disease.
PDS with ranibizumab is proving to be an innovation solution for nAMD patients. Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 ASRS annual meeting.
The results of the Protocol T Extension Study underscore the need for methods to improve long-term visual gains in eyes with diabetic macular edema, according to Dante Pieramici, MD, on behalf of the DRCR Retina Network, during the American Society of Retina Specialists 2020 Virtual Annual Meeting.
Carl Danzig, MD, presented results of phase 2 Stairway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
An augmented-reality device provides AMD patients with enhanced reading ability and facial recognition.
Intravitreal liposome-encapsulated bromfenac is under study as a treatment for refractory DME. Results of a pilot study were detailed at the virtual 2020 ASRS annual meeting.
The Audacious Goals Initiative of the National Eye Institute is focused on developing noninvasive imaging advances to help patients with vision loss.
These imaging technologies can help with assessing unexpected structural and vascular retinal and choroidal changes in active and post-treatment toxoplasmic retinochoroiditis.
The study authors hypothesized that patients poorly responding to ranibizumab may have resulted from tachyphylaxis or tolerance to the drug and regarding the nonresponders, they speculated that VEGF-A may not have been the main cause of the neovascular growth.
A study of adult patients with diabetes found that bowtie-shaped polarization artifacts do not serve as reliable clinical biomarkers for center-involving diabetic macular edema. What might this mean for clinicians?
Treatment with a single ocriplasmin injection led to clinically meaningful improvements in the patient-reported visual function measured by the VFQ-25 questionnaire over 24 months in patients with symptomatic vitreomacular adhesion.
Only 2% of patients with internal limiting membrane peeling developed an epiretinal membrane compared with 46% with no peeling.
Fundus autofluorescence is a helpful tool for diagnosing central serous choroidopathy and planning treatment.
Immediate administration after radiation therapy is key.
This study provided clinical proof of concept for viral vector-mediated gene supplementation therapy of inherited day blindness caused by pathogenic variants in the cone photoreceptor-specific gene CNGA3.
